ScreenerHero

ADILAdial Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · adial.com
6.215USD+7.99%Mkt Cap: 16.32M $P/E: —

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap16.32M $
Enterprise Value25.31M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.98M $
Revenue/Share—
Last Price6.215 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.79
PEG—
EV/EBITDA-2.20
EV/Revenue—
P/S—
P/B-0.40
EPS (TTM)-18.02
EPS (Forward)-7.45
52W Range
1.31052% of range10.75
52W High10.75 USD
52W Low1.310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.18%
ROA-119.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.49M $
CapEx (TTM)—
FCF Margin—
FCF Yield-25.91%
Net Debt-28.71M $
Net Debt/EBITDA2.50
Balance Sheet
Debt/Equity—
Current Ratio5.63
Quick Ratio5.61
Book Value/Sh-14.6150 USD
Cash/Share10.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)8.333 USD
Upside (mean)+34.1%
Target Range6.000 USD – 11.00 USD
$6.000+34.1% to mean$11.00
# Analysts3
Ownership
Shares Out.2.63M
Float1.64M
Insiders4.25%
Institutions30.30%
Short Interest
Short Ratio5.3d
Short % Float10.74%
Short % Out.10.68%
Shares Short233.65K
Short (prev mo.)230.98K
Technical
SMA 503.268 (+90.2%)
SMA 2003.836 (+62.0%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)63.45K
Avg Vol (10d)73.71K
Technical Indicators
RSI (14)78.4
MACD0.6811
MACD Signal0.4909
MACD Hist.+0.1902
BB Upper5.903 USD
BB Middle3.966 USD
BB Lower2.029 USD
BB Width97.70%
ATR (14)0.4930 USD
Vol Ratio (20d)1.14x